Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. The company has additional operations facilities in Huntsville, Alabama... Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. The company has additional operations facilities in Huntsville, Alabama, and Hyderabad, India. Show more
Nektar Therapeutics Presents First Preclinical Data on NKTR-0165, a TNFR2 Agonist Antibody Being Developed for the Treatment of Inflammatory Diseases, at EULAR 2024 PR Newswire SAN FRANCISCO...
Nektar Management to Present at Upcoming Investor Conferences PR Newswire SAN FRANCISCO, May 30, 2024 SAN FRANCISCO, May 30, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) management is...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.01 | -0.8 | 1.25 | 1.34 | 1.1 | 1883071 | 1.24721874 | CS |
4 | -0.02 | -1.5873015873 | 1.26 | 1.385 | 1.01 | 1660957 | 1.18628201 | CS |
12 | -0.44 | -26.1904761905 | 1.68 | 1.928 | 1.01 | 1746986 | 1.41220498 | CS |
26 | 0.6899 | 125.413561171 | 0.5501 | 1.928 | 0.48 | 1992519 | 1.15646602 | CS |
52 | 0.672 | 118.309859155 | 0.568 | 1.928 | 0.4126 | 2872024 | 0.9292436 | CS |
156 | -15.19 | -92.4528301887 | 16.43 | 19.37 | 0.4126 | 2805269 | 3.4797799 | CS |
260 | -33.78 | -96.4591661907 | 35.02 | 35.31 | 0.4126 | 2342693 | 8.27067415 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.